Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Q1 2022 Earnings Presentation
16 slides from Innate Pharma Sa Class A's earnings presentation, May 10, 2022
Slide 1: First Quarter 2022 Business Update
First Quarter 2022 Business Update May 10, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi, MD Joyson Karakunnel, MD, MSc, FACP Chief Executive Officer EVP, Chief Medical Officer Chairman of the Executive Board Yannis Morel, PhD Frédéric Lombard, MBA EVP, Business Development and SVP, Chief Financial Officer Product Portfolio Strategy (Q&A) 3
Slide 4: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Drive near-term Advance our Build sustainable value with innovative R&D business through Lacutamab pipeline partnerships • TELLOMAK all comers cohort • IPH6101 ANKETTM Phase 1 trial • PACIFIC-9 Phase 3 NSCLC start opened underway • $50M
Slide 5: PACIFIC-9, Phase 3 clinical trial with monalizumab in NSCLC
PACIFIC-9, Phase 3 clinical trial with monalizumab in NSCLC $50 million milestone payment received from AstraZeneca on first patient dosed in Phase 3 trial, PACIFIC-9 Potential amounts to be Milestone Payments (in millions of US $) Amounts received collected Total of Potential Payments 1,275 Initial
Slide 6: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Sézary Syndrome TELLOMAK PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data expected 2022 Early data presented Mycosis Fungoides TELLOMAK PHASE 2 Prelimina
Slide 7: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary Syndrome (N~60) Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2# Cohort 3# All Comers* All comers, SS, must include KIR3DL
Slide 8: Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas
Developing a New Standard of Care Across KIR3DL2- Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sezary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients ~18,000 p
Slide 9: Monalizumab: Early NSCLC
MONALIZUMAB Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* Stg I-IIIA NSCLC Unresect. Stg III NSCLC monali
Slide 10: Monalizumab: Head and Neck cancer
MONALIZUMAB Monalizumab: Head and Neck cancer Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN SCCHN 2L+ Phase 3 trial underway R/M SCCHN 1L 2L+ Phase 2 Cohort 3 Phase 2 Cohort 2 1L R/M SCCHN Post PDx R/R SCCHN monalizumab + durvalumab + cetuximab monal
Slide 11: Adenosine Pathway: IPH5201 (anti CD39) and IPH5301 (anti CD73)
ADENOSINE Adenosine Pathway: IPH5201(anti CD39) and IPH5301 (anti CD73) Clinical trials underway IPH5201* (anti CD39): Phase 1 clinical trial design Combination Monotherapy IPH5201 IPH5201 + durvalumab PART 1 PART 2 IPH5301 (anti CD73): Design of the Phase 1 clinical trial ISS CHANCES Tumor spreadin
Slide 12: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for- purpose technology that is creating Provides proliferation and activation signals
Slide 13: Key Newsflow Over the Next 2 Years
Key Newsflow Over the Next 2 Years 2 0 2 2 Data Readouts Clinical Progress • Monalizumab NeoCOAST Ph2 NSCLC (AstraZeneca) AACR • Monalizumab PACIFIC-9 NSCLC Phase 3 start (AstraZeneca) • Lacutamab Phase 2 MF data (preliminary) H2 • Monalizumab NeoCOAST-2 Phase 2 start (AstraZeneca) • Lacutamab Phase
Slide 14: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Lacutamab R&D pipeline Partnerships • TELLOMAK read-out with MF in • Advancing proprietary tetra- • Strong Phase 3 monalizumab 2021 and preliminary data for MF specific NK cell-targeted platform collaboration with AstraZeneca and SS in
Slide 15: Questions and Answers
Questions and Answers &S innate pharma
Slide 16: Monalizumab: NSCLC
MONALIZUMAB Monalizumab : NSCLC 2021 and AACR 2022 data presentations provide rationale for further exploration in NSCLC NeoCOAST: open-label, randomized, Phase 2, multidrug platform study of COAST: Phase 2 study of durvalumab alone or in combination with novel agents in neoadjuvant durvalumab alone